SCHEMBL1507955

SCHEMBL1507955

CCOP(=O)(O)C(c1ccc(F)cc1)(c1ccc(F)cc1)c1ccc(F)cc1

nearest known ligand 0.42

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.42
KCNN4 O15554 3/20 0.39
KDM4E B2RXH2 2/20 0.38
KMT2A Q03164 3/20 0.38
LMNA P02545 3/20 0.38
MEN1 O00255 2/20 0.38
GAA P10253 1/20 0.38
NR1I2 O75469 1/20 0.36
HMGCR P04035 1/20 0.36
TSHR P16473 1/20 0.35
MAPT P10636 2/20 0.35
CYP1A2 P05177 1/20 0.35
CYP2C9 P11712 1/20 0.35
CYP2C19 P33261 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35
RAB9A P51151 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1508255 0.92 KMT2A (0.42) ALDH1A1KDM4EKMT2ALMNAMEN1
SCHEMBL1508218 0.89 KCNN4 (0.47) ALDH1A1KCNN4KDM4EKMT2ALMNA
SCHEMBL1508012 0.85 KCNN4 (0.47) ALDH1A1KCNN4KDM4EKMT2ALMNA
SCHEMBL1508095 0.82 HDAC6 (0.40) ALDH1A1KDM4EKMT2AMEN1RAB9A
SCHEMBL1507922 0.81 ALOX15 (0.38) ALDH1A1KMT2ALMNAMEN1GAA
SCHEMBL1508245 0.81 ALDH1A1 (0.42) ALDH1A1KCNN4KDM4EKMT2ALMNA
SCHEMBL1508149 0.79 KCNN4 (0.41) ALDH1A1KCNN4KDM4EKMT2ALMNA
SCHEMBL1508117 0.79 ALDH1A1 (0.40) ALDH1A1KCNN4KDM4EKMT2ALMNA
SCHEMBL1508167 0.77 GAA (0.38) ALDH1A1GAA
SCHEMBL8795835 0.76 KMT2A (0.39) ALDH1A1KCNN4KDM4EKMT2ALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2292595-A1 Potassium channel modulators NeuroSearch AS (DK) 2011-03-09 EP claimed
US-7429618-B2 Potassium channel modulators NEUROSEARCH A/S (DK) 2008-09-30 US claimed
EP-1911740-A1 POTASSIUM CHANNEL MODULATORS NeuroSearch A/S (DK) 2008-04-16 EP claimed
US-20070161607-A1 Potassium channel modulators SANIONA A/S (DK) 2007-07-12 US claimed
US-20050009816-A1 Potassium channel modulators SANIONA A/S (DK) 2005-01-13 US claimed
EP-1465863-A1 POTASSIUM CHANNEL MODULATORS Poseidon Pharmaceuticals A/S (DK) 2004-10-13 EP claimed
WO-2003059873-A1 POTASSIUM CHANNEL MODULATORS POSEIDON PHARMACEUTICALS A/S (DK) 2003-07-24 WO claimed
EP-2292595-A1 Potassium channel modulators NeuroSearch AS (DK) 2011-03-09 EP disclosed
US-7429618-B2 Potassium channel modulators NEUROSEARCH A/S (DK) 2008-09-30 US disclosed
EP-1911740-A1 POTASSIUM CHANNEL MODULATORS NeuroSearch A/S (DK) 2008-04-16 EP disclosed
US-20070161607-A1 Potassium channel modulators SANIONA A/S (DK) 2007-07-12 US disclosed
US-7208527-B2 Potassium channel modulators POSEIDON PHARMACEUTICALS A/S (DK) 2007-04-24 US disclosed
US-20050009816-A1 Potassium channel modulators SANIONA A/S (DK) 2005-01-13 US disclosed
EP-1465863-A1 POTASSIUM CHANNEL MODULATORS Poseidon Pharmaceuticals A/S (DK) 2004-10-13 EP disclosed
WO-2003059873-A1 POTASSIUM CHANNEL MODULATORS POSEIDON PHARMACEUTICALS A/S (DK) 2003-07-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050009816-A1 Potassium channel modulators KCNC1, KCNQ1, KCNA1 ALDH1A1 3877/4885KCNN4 48/4885KDM4E 405/4885
US-20070161607-A1 Potassium channel modulators KCNC1, KCNQ1, KCNA1 ALDH1A1 3877/4885KCNN4 48/4885KDM4E 405/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.